Methyl (2S,4R)-4-Hydroxypyrrolidine-2-Carboxylate Hydrochloride

In the kilogram-scale preparation of macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitors such as grazoprevir (MK-5172), stereochemical integrity of the (2S,4R)-4-hydroxypyrrolidine-2-carboxylate scaffold is the dominant quality attribute determining downstream coupling efficiency and final active pharmaceutical ingredient (API) purity. Methyl (2S,4R)-4-Hydroxypyrrolidine-2-Carboxylate Hydrochloride is typically liberated to its free base using 1.05 – 1.15 equivalents of N-methylmorpholine (NMM) in anhydrous tetrahydrofuran (THF) at 0 ± 3°C in a jacketed glass-lined reactor equipped with a retreat-curve impeller operating at 120 – 150 rpm. Failure to maintain the internal temperature below 5°C during the neutralization and subsequent acylation with the quinoline-carboxylic acid fragment results in baseline-resolvable epimerization at the C2 ester methine, detectable by chiral HPLC as a secondary peak eluting at a relative retention time (RRT) of 1.12 versus the desired (2S,4R) diastereomer. The acylation step itself employs 1.3 equivalents of the pre-activated acid—generated with HATU (1.4 eq) and N,N-diisopropylethylamine (DIPEA, 3.0 eq) in DMF—and is dosed over 45 – 60 minutes while the reaction mass is held at -15 ± 2°C to suppress diketopiperazine formation and transesterification side paths. Process analytical technology (PAT) integrating ReactIR 15 with a 6 mm DiComp diamond ATR probe continuously monitors the disappearance of the ester carbonyl stretch at 1740 cm⁻¹. After aqueous work-up and crystallization from methyl tert-butyl ether (MTBE)/n-heptane (1:4 v/v), the isolated macrocyclic intermediate achieves an enantiomeric excess exceeding 99.8% as measured on a Chiralpak IC column (250 × 4.6 mm, 5 µm) with a mobile phase of n-hexane/ethanol/diethylamine (70/30/0.1 v/v/v) at 1.0 mL/min and UV detection at 254 nm. The final grazoprevir API crystallizes as a non-solvated anhydrous polymorph with a melting onset of 207 – 209°C by differential scanning calorimetry (DSC) at 10 K/min under nitrogen purge. Residual Methyl (2S,4R)-4-Hydroxypyrrolidine-2-Carboxylate Hydrochloride or its ring-opened derivatives are controlled below 0.10% area percentage in the API release specification according to ICH Q3A guidelines, with quantitation performed by UPLC-UV against an external standard of known purity traceable to a certified reference material.

Incorporation of Methyl (2S,4R)-4-Hydroxypyrrolidine-2-Carboxylate Hydrochloride into a growing peptide chain on 2-chlorotrityl chloride resin (loading 0.8 – 1.2 mmol/g) imposes a characteristic kink angle of approximately 120° between the i and i+2 residues, a conformational constraint exploited in the solid-phase synthesis of orally bioavailable macrocyclic peptide mimetics targeting protein–protein interfaces such as the CXCR4 chemokine receptor or MDM2/p53. The building block is first Fmoc-protected at the pyrrolidine nitrogen under Schotten-Baumann conditions (Fmoc-OSu, 1.1 eq, Na₂CO₃, dioxane/H₂O 2:1) to yield Fmoc-(2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid methyl ester. The secondary 4-hydroxyl group remains unprotected to minimize steric bulk during on-resin couplings; alternatively, when extended sequences are assembled, a TBDMS ether is installed using TBDMSCl (2.5 eq) and imidazole (5.0 eq) in DMF and retained until the penultimate deprotection stage. Coupling of the Fmoc-amino acid onto the resin-bound peptide is mediated by HCTU (3.0 eq) in N-methyl-2-pyrrolidone (NMP) with 0.1 M HOAt as an additive, and double coupling cycles of 45 minutes each are mandated when the sterically encumbered pyrrolidine nitrogen of the preceding residue is a Pro or Hyp derivative. N-terminal Fmoc removal uses 20% piperidine in DMF (v/v) in two stages of 5 and 15 minutes to avoid aspartimide formation, monitored qualitatively by the Kaiser test and quantitatively by UV absorbance at 301 nm. Cleavage from the resin with 30% hexafluoroisopropanol (HFIP) in DCM preserves the methyl ester, enabling subsequent head-to-tail macrocyclization in the solution phase under pseudodilution conditions: linear peptide concentration 1 mM in DMF, DPPA (3.0 eq), and solid NaHCO₃ (10 eq) at 4°C for 72 hours. The resulting 16- to 18-membered macrocycle exhibits a single dominant conformer by ¹H NMR (DMSO-d₆, 600 MHz) with the exocyclic methyl ester hydrolyzed in the final step using LiOH (1.2 eq) in THF/H₂O (3:1) at 0°C to liberate the free carboxylic acid pharmacophore. This sequence has been executed on a 10-mmol scale with a crude macrocycle purity of 78 – 82% prior to preparative HPLC purification on a C18 stationary phase.

Pyrrolidine-Derived Asymmetric Organocatalysts for Iminium and Enamine Activation

Transformation of Methyl (2S,4R)-4-Hydroxypyrrolidine-2-Carboxylate Hydrochloride into second-generation Jørgensen-Hayashi-type diarylprolinol silyl ethers requires rigorous exclusion of moisture and maintenance of the (2S,4R) configuration throughout a Grignard addition–reduction sequence. The hydrochloride salt is suspended in anhydrous THF (Kf ≤ 30 ppm) and free-based with triethylamine (2.2 eq) under argon counterflow. After filtration of triethylammonium chloride in a glovebox with oxygen and moisture levels below 0.5 ppm, the filtrate is added dropwise into a solution of the appropriate aryl Grignard reagent—most commonly 3,5-bis(trifluoromethyl)phenylmagnesium bromide—prepared from the corresponding aryl bromide and magnesium turnings (iodine-activated) in diethyl ether, with the exchange to THF effected by distillation under reduced pressure. The methyl ester solution is introduced at -78°C over 30 minutes using a syringe pump, and the reaction mixture is warmed to -20°C over 3 hours before quenching with saturated aqueous NH₄Cl. Under these conditions, the tertiary alcohol is obtained as the dominant product with less than 3% of the ketone intermediate persisting after work-up, as assessed by TLC (silica gel 60 F₂₅₄, hexane/ethyl acetate 3:1). The crude diarylprolinol is then subjected to N-Boc protection (Boc₂O, 1.5 eq, THF, rt) followed by silylation of the primary hydroxyl—generated by selective reduction of the ester residue during the Grignard reaction—with TMSCl (2.0 eq) and imidazole (4.0 eq), yielding the catalytically active O-TMS-diarylprolinol in an overall yield of 55 – 62% from the hydrochloride starting material. This organocatalyst promotes the asymmetric Michael addition of aldehydes to nitrostyrenes with enantioselectivities up to 97% ee (determined by chiral GC on a Lipodex E column) when employed at 10 mol% loading in toluene at 4°C. Manufacturing-scale batches require specification testing for the absence of des-silyl and de-borylated by-products by ¹⁹F NMR integration using α,α,α-trifluorotoluene as an internal standard.

When the C7-piperazinyl substituent of a veterinary fluoroquinolone such as pradofloxacin is replaced with a (3S,4R)-4-aminopyrrolidine moiety to improve gram-positive potency and reduce phototoxicity, Methyl (2S,4R)-4-Hydroxypyrrolidine-2-Carboxylate Hydrochloride serves as the chirally defined starting point for the requisite vicinal amino-alcohol pharmacophore. The 4-hydroxyl group is first activated as the mesylate (MsCl, 2.0 eq, DIPEA, DCM, -10°C) and subsequently displaced with sodium azide (3.0 eq) in DMSO at 40°C for 16 hours under a nitrogen atmosphere to avert the accumulation of hydrazoic acid vapor, with online FTIR monitoring of the azide peak at 2100 cm⁻¹ confirming complete substitution. Catalytic hydrogenation of the resulting azido ester over 5% Pd/C (Johnson Matthey type 87L, 10 wt% loading) in methanol at 3 bar H₂ pressure in a Parr stirred reactor yields the saturated (3S,4R)-4-aminopyrrolidine hydrochloride after in situ N-Boc cleavage and HCl salt formation. The methyl ester of the intermediate is hydrolyzed with 6 N HCl under reflux (105°C oil bath) to the corresponding amino acid, which is then coupled to the fluoroquinolone carboxylic acid core using BOP-Cl (1.3 eq) and N-methylmorpholine in acetonitrile. The final analogue exhibits a minimum inhibitory concentration (MIC) against community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) strains that is 2 – 4-fold lower than that of the parent piperazinyl derivative, as determined by broth microdilution in cation-adjusted Mueller-Hinton II medium (CLSI standard M07). Residual palladium in the isolated API intermediate is controlled below 10 ppm per ICH Q3D (Class 1 metal) via hot filtration through a 0.2 µm PTFE membrane and subsequent treatment with Si-thiol scavenger resin.

Collagen Triple-Helix Stabilization Through Pre-Organized (2S,4R)-4-Hydroxyproline Methyl Ester Building Blocks

Solid-phase assembly of collagen-model peptides (CMPs) with the repeating sequence (Pro-Hyp-Gly)₇ requires the stereodefined (2S,4R)-trans-4-hydroxyproline configuration to ensure the characteristic thermal melting transition monitored by circular dichroism (CD) at 225 nm. Direct use of Methyl (2S,4R)-4-Hydroxypyrrolidine-2-Carboxylate Hydrochloride in automated microwave-assisted SPPS (CEM Liberty Blue, 0.1 mmol scale) eliminates the time-consuming solution-phase synthesis of Fmoc-Hyp(tBu)-OH. The hydrochloride salt is neutralized in situ during cartridge activation by dissolving in DMF containing 0.5 M DIPEA (2.2 eq relative to HCl content) and then coupled to the deprotected peptidyl resin using HATU (4.0 eq) in the presence of 0.5 M Oxyma Pure. Double coupling cycles of 2 minutes at 75°C with a 20 W microwave power limitation avoid racemization at the C2 position, verified post-cleavage by Marfey’s analysis using FDAA derivatization and LC-MS detection. The crude peptide is cleaved with TFA/TIS/H₂O (95:2.5:2.5) and precipitated from cold diethyl ether, and the C-terminal methyl ester is left intact to assess the influence of a non-ionizable terminus on triple-helix folding kinetics. CD melts recorded in 10 mM phosphate-buffered saline (pH 7.4) from 5 to 80°C at a rate of 0.5°C/min show a cooperative unfolding profile with a midpoint temperature (T_m) of 42 ± 1°C, 4°C higher than that of the corresponding C-terminal acid, attributable to reduced electrostatic repulsion at the chain termini. Batch-to-batch consistency in T_m values correlates with the enantiomeric purity of the starting hydroxyproline ester, and a specification of ≥ 99.0% ee is enforced by supplier qualification using chiral supercritical fluid chromatography (SFC) on a Chiralpak AD-H column (150 × 4.6 mm, 5 µm) with a CO₂/methanol (80:20) mobile phase at 3.0 mL/min and a backpressure regulator setting of 120 bar.

Thorough identification and quantification of process-related impurities in pharmaceutical intermediates require a well-characterized reference standard of Methyl (2S,4R)-4-Hydroxypyrrolidine-2-Carboxylate Hydrochloride, certified for identity, assay, and chromatographic purity. A single production batch intended for use as an impurity marker in the final API of a macrocyclic protease inhibitor undergoes a multi-technique purification protocol: recrystallization from absolute ethanol/diethyl ether (1:3) at -20°C under nitrogen, followed by vacuum drying at 40°C and ≤ 5 mbar for 48 hours to reduce volatiles below the threshold specified in Ph. Eur. General Chapter 2.2.32. The lot is then subjected to a mass balance assessment comprising quantitative ¹H NMR (qNMR) using a 600 MHz spectrometer with a cryogenically cooled probe and dimethyl sulfone certified standard (NIST SRM 136f) as internal calibrant, Karl Fischer coulometric water determination (≤ 0.05% w/w), residual solvent analysis by headspace GC-FID (residual ethanol ≤ 100 ppm), and sulfated ash. The assigned purity, typically 99.7 ± 0.2% (k = 2 confidence interval), is stated on the certificate of analysis and is traceable to the International System of Units (SI) through the NIST standard. The reference material is stored in sealed ampoules under argon at -20°C and retested every 12 months against a freshly recrystallized control to verify stability relative to the initial purity assignment. UPLC-MS/MS methods with a limit of detection (LOD) of 0.01% for the (2R,4S) enantiomer and the ring-degradation pyroglutamate analogue are validated per ICH Q2(R1) guidelines using this reference batch to set system suitability criteria for resolution (R_s > 2.0) and signal-to-noise ratio at the reporting threshold.